Q1 EPS Forecast for Neumora Therapeutics Boosted by Analyst

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Analysts at William Blair boosted their Q1 2025 EPS estimates for shares of Neumora Therapeutics in a research report issued to clients and investors on Monday, March 3rd. William Blair analyst M. Minter now forecasts that the company will post earnings of ($0.37) per share for the quarter, up from their previous forecast of ($0.47). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. William Blair also issued estimates for Neumora Therapeutics’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.85) EPS, FY2028 earnings at ($1.48) EPS and FY2029 earnings at ($0.26) EPS.

Several other research analysts have also weighed in on the stock. HC Wainwright cut their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. Finally, Bank of America cut their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Neumora Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Neumora Therapeutics Trading Up 6.3 %

NASDAQ:NMRA opened at $1.52 on Thursday. The firm has a market cap of $245.57 million, a price-to-earnings ratio of -0.81 and a beta of 2.59. The company’s 50-day moving average is $2.63 and its two-hundred day moving average is $8.71. Neumora Therapeutics has a 12-month low of $1.35 and a 12-month high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

Institutional Trading of Neumora Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Neumora Therapeutics during the 4th quarter worth approximately $61,000. PNC Financial Services Group Inc. acquired a new stake in Neumora Therapeutics during the 4th quarter worth approximately $64,000. Quantbot Technologies LP acquired a new stake in Neumora Therapeutics during the 4th quarter worth approximately $92,000. PEAK6 LLC acquired a new stake in Neumora Therapeutics during the 4th quarter worth approximately $117,000. Finally, EntryPoint Capital LLC acquired a new stake in Neumora Therapeutics in the fourth quarter valued at approximately $135,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.